ARCT logo

ARCT
Arcturus Therapeutics Holdings Inc

5,498
Mkt Cap
$238.75M
Volume
12.00
52W High
$24.17
52W Low
$5.85
PE Ratio
-3.52
ARCT Fundamentals
Price
$8.40
Prev Close
$8.87
Open
$8.75
50D MA
$7.80
Beta
1.68
Avg. Volume
575,621.95
EPS (Annual)
-$2.40
P/B
1.12
Rev/Employee
$605,594.59
$38.03
Loading...
Loading...
News
all
press releases
Arcturus Therapeutics (NASDAQ:ARCT) Shares Cross Below 200 Day Moving Average - Time to Sell?
Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below 200-Day Moving Average - What's Next...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 7, 2026
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...
Business Wire·3d ago
News Placeholder
Diversify Advisory Services LLC Sells 115,500 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
Diversify Advisory Services LLC reduced its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 88.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,00...
MarketBeat·13d ago
News Placeholder
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Rating of "Moderate Buy" from Brokerages
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the thirteen brokerages that are currently covering the firm...
MarketBeat·16d ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below Two Hundred Day Moving Average - What's Next?
Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below Two Hundred Day Moving Average - What's Next...
MarketBeat·20d ago
News Placeholder
Hennion & Walsh Asset Management Inc. Purchases 161,910 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
Hennion & Walsh Asset Management Inc. grew its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 206.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 240,303 shares of the biotechnology company's stock after buying an additional 16...
MarketBeat·28d ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below 200 Day Moving Average - Should You Sell?
Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below Two Hundred Day Moving Average - Here's What Happened...
MarketBeat·29d ago
News Placeholder
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf
Arcturus Therapeutics (NASDAQ:ARCT) CEO Joe Payne told investors at the 38th Annual ROTH Conference that the company is refocusing on rare disease programs after gaining approvals for its COVID-19 vaccine in more than 30 countries. Payne said Arcturus had initiated a rare disease strategy for messen...
MarketBeat·1mo ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by B. Riley Financial
B. Riley Financial upgraded Arcturus Therapeutics to a "strong-buy" rating in a research report on Tuesday...
MarketBeat·1mo ago
News Placeholder
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Moderate Buy" from Analysts
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the thirteen brokerages that are currently covering the stock...
MarketBeat·1mo ago
<
1
2
...
>

Latest ARCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.